These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 37698500)

  • 1. Pneumococcal infections in children with sickle cell disease before and after pneumococcal conjugate vaccines.
    Adamkiewicz TV; Yee MEM; Thomas S; Tunali A; Lai KW; Omole FS; Lane PA; Yildirim I
    Blood Adv; 2023 Nov; 7(21):6751-6761. PubMed ID: 37698500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines.
    Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA
    Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.
    Ben-Shimol S; Regev-Yochay G; Givon-Lavi N; van der Beek BA; Brosh-Nissimov T; Peretz A; Megged O; Dagan R; ;
    Clin Infect Dis; 2022 May; 74(9):1639-1649. PubMed ID: 34293091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine.
    Sharma D; Baughman W; Holst A; Thomas S; Jackson D; da Gloria Carvalho M; Beall B; Satola S; Jerris R; Jain S; Farley MM; Nuorti JP
    Pediatr Infect Dis J; 2013 Feb; 32(2):e45-53. PubMed ID: 23080290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Invasive Pneumococcal Disease in Children with Sickle Cell Disease in England: A National Observational Cohort Study, 2010-2015.
    Oligbu G; Collins S; Sheppard C; Fry N; Dick M; Streetly A; Ladhani S
    Arch Dis Child; 2018 Jul; 103(7):643-647. PubMed ID: 29282225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
    Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
    Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies.
    Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD
    Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Invasive pneumococcal disease among children with and without sickle cell disease in the United States, 1998 to 2009.
    Payne AB; Link-Gelles R; Azonobi I; Hooper WC; Beall BW; Jorgensen JH; Juni B; Moore M;
    Pediatr Infect Dis J; 2013 Dec; 32(12):1308-12. PubMed ID: 23811745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
    Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
    BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical modeling of pneumococcal transmission dynamics in response to PCV13 infant vaccination in Germany predicts increasing IPD burden due to serotypes included in next-generation PCVs.
    Horn M; Theilacker C; Sprenger R; von Eiff C; Mahar E; Schiffner-Rohe J; Pletz MW; van der Linden M; Scholz M
    PLoS One; 2023; 18(2):e0281261. PubMed ID: 36791091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
    Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
    Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of invasive pneumococcal disease in children with sickle cell disease in the era of conjugate vaccines: a systematic review of the literature.
    Oligbu G; Fallaha M; Pay L; Ladhani S
    Br J Haematol; 2019 May; 185(4):743-751. PubMed ID: 30859558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF; McCallum L; Fathima P; Moore HC; Snelling TL; Blyth CC; Jayasinghe S; Giele C; de Klerk N; Andrews RM; McIntyre PB;
    Vaccine; 2018 May; 36(19):2650-2656. PubMed ID: 29627233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nationwide population-based surveillance of invasive pneumococcal disease in Japanese children: Effects of the seven-valent pneumococcal conjugate vaccine.
    Suga S; Chang B; Asada K; Akeda H; Nishi J; Okada K; Wakiguchi H; Maeda A; Oda M; Ishiwada N; Saitoh A; Oishi T; Hosoya M; Togashi T; Oishi K; Ihara T
    Vaccine; 2015 Nov; 33(45):6054-60. PubMed ID: 26235372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
    Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
    Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
    Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.